KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 5,296 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Paul Audhya sold 5,296 shares of the company’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $13.45, for a total value of $71,231.20. Following the sale, the insider owned 131,831 shares in the company, valued at approximately $1,773,126.95. This trade represents a 3.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

KalVista Pharmaceuticals Price Performance

KalVista Pharmaceuticals stock traded up $0.82 during trading hours on Thursday, reaching $14.10. The stock had a trading volume of 1,928,887 shares, compared to its average volume of 933,997. The company has a market cap of $712.70 million, a price-to-earnings ratio of -3.58 and a beta of -0.04. The business’s 50 day moving average price is $12.04 and its 200-day moving average price is $12.87. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $17.28.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) EPS for the quarter, topping analysts’ consensus estimates of ($0.96) by $0.04. The firm had revenue of $13.69 million for the quarter, compared to analyst estimates of $6.03 million. On average, sell-side analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently issued reports on KALV shares. JMP Securities boosted their price objective on KalVista Pharmaceuticals from $27.00 to $28.00 and gave the company a “market outperform” rating in a report on Friday, September 12th. Citigroup reiterated a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday, November 11th. Weiss Ratings restated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research report on Friday, September 12th. Finally, Citizens Jmp lowered their price objective on KalVista Pharmaceuticals from $29.00 to $28.00 and set a “market outperform” rating on the stock in a report on Tuesday, November 11th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.63.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of KALV. Earned Wealth Advisors LLC acquired a new position in KalVista Pharmaceuticals in the first quarter valued at approximately $44,000. BNP Paribas Financial Markets raised its position in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company’s stock valued at $46,000 after purchasing an additional 1,292 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of KalVista Pharmaceuticals during the 3rd quarter worth about $55,000. CWM LLC raised its holdings in KalVista Pharmaceuticals by 12,636.1% in the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock valued at $53,000 after buying an additional 4,549 shares during the period. Finally, Wolverine Asset Management LLC acquired a new position in KalVista Pharmaceuticals in the third quarter valued at about $57,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).